Form 4: ANI Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, sold shares of common stock between July 15 and July 17, 2024, under a pre-arranged trading plan.
Summary
- Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, executed sales of common stock between July 15 and July 17, 2024.
- The sales were conducted under a Rule 10b5-1 trading plan adopted on November 27, 2023.
- On July 15, 2024, 11,000 shares were sold at a weighted average price of $63.38.
- On July 16, 2024, 22,000 shares were sold at a weighted average price of $64.27.
- On July 17, 2024, 14,257 shares were sold at a weighted average price of $63.16.
- Following these transactions, Shanmugam directly owns 68,652 shares and indirectly owns 635,363 shares through Esjay LLC and 5,000 shares through SS Pharma LLC.
- Shanmugam holds voting and dispositive power over the shares held by Esjay LLC and SS Pharma LLC.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions.
Industry Context
Sales by insiders are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| November 27, 2023 | Date the reporting person adopted the Rule 10b5-1 trading plan |
| July 15, 2024 | Date of first reported transaction |
| July 16, 2024 | Date of second reported transaction |
| July 17, 2024 | Date of third reported transaction and filing date of the Form 4 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.